Ikaros and childhood acute lymphoblastic leukemia

Abstract

YI Li-Jun-；Duan-Jun-Kai-；Li-Hong. Ikaros and childhood acute lymphoblastic leukemia[J]. Journal of International Oncology, 2015, 42(4): 316-318.

［1］ Cobb BS, MoralesAlcelay S, Kleiger G, et al. Targeting of Ikaros to pericentromeric heterochromatin by direct DNA binding［J］. Genes Dev, 2000, 14(17): 21462160. ［2］ Ishimaru F. Expression of Ikaros isoforms in acute lymphoblastic leukemia cell lines［J］. J Clin Oncol, 2000, 18(6): 13951397. ［3］ Dovat S, Payne KJ. Tumor suppression in T cell leukemia—the role of Ikaros［J］. Leuk Res, 2010, 34(4): 416417. ［4］ Meyer C, Zur Stadt U, Escherich G, et al. Refinement of IKZF1 recombination hotspots in pediatric BCPALL patients［J］. Am J Blood Res, 2013, 3(2): 165173. ［5］ Sellars M, Kastner P, Chan S. Ikaros in B cell development and function［J］. World J Biol Chem, 2011, 2(6): 132139. ［6］ Ma S, Pathak S, Mandal M, et al. Ikaros and aiolos inhibit preBcell proliferation by directly suppressing cMyc expression［J］. Mol Cell Biol, 2010, 30(17): 41494158. ［7］ Lo K, Landau NR, Smale ST. LyF1, a transcriptional regulator that interacts with a novel class of promoters for lymphocytespecific genes［J］. Mol Cell Biol, 1991, 11(10): 52295243. ［8］ Georgopoulos K, Moore DD, Derfler B. Ikaros, an early lymphoidspecific transcription factor and a putative mediator for T cell commitment［J］. Science, 1992, 258(5083): 808812. ［9］ Lopez RA, Schoetz S, DeAngelis K, et al. Multiple hematopoietic defects and delayed globin switching in Ikaros null mice［J］. Proc Natl Acad Sci USA, 2002, 99(2): 602607. ［10］ Ng SY, Yoshida T, Zhang J, et al. Genomewide lineagespecific transcriptional networks underscore Ikarosdependent lymphoid priming in hematopoietic stem cells［J］. Immunity, 2009, 30(4): 493507. ［11］ Kim J, Sif S, Jones B, et al. Ikaros DNA binding proteins direct formation of chromatin remodeling complexes in lymphocytes［J］. Immunity, 1999, 10(3): 345355. ［12］ Sridharan R, Smale ST. Predominant interaction of both Ikaros and Helios with the NuRD complex in immature thymocytes［J］. J Biol Chem, 2007, 282(41): 3022730238. ［13］ Kathrein KL, Chari S, Winandy S. Ikaros directly represses the notch target gene Hes1 in a leukemia T cell line: implications for CD4 regulation［J］. J Biol Chem, 2008, 283(16): 1047610484. ［14］ Papaemmanuil E, Hosking FJ, Vijayakrishnan J, et al. Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia［J］. Nat Genet, 2009, 41(9): 10061010. ［15］ Heerema NA, Nachman JB, Sather HN, et al. Deletion of 7p or monosomy 7 in pediatric acute lymphoblastic leukemia is an adverse prognostic factor: a report from the Children′s Cancer Group［J］. Leukemia, 2004, 18(5): 939947. ［16］ Dupuis A, Gaub MP, Legrain M, et al. Biclonal and biallelic deletions occur in 20% of BALL cases with IKZF1 mutations［J］. Leukemia, 2013, 27(2): 503507. ［17］ Yoshida T, Georgopoulos K. Ikaros fingers on lymphocyte differentiation［J］. Int J Hematol, 2014, 100(3): 220229. ［18］ Virely C, Moulin S, Cobaleda C, et al. Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCRABL in a transgenic model of acute lymphoblastic leukemia［J］. Leukemia, 2010, 24(6): 12001204. ［19］ Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A subtype of children acute lymphoblastic leukaemia with poor treatment outcom: a genomewide classification study［J］. Lancet Oncol, 2009, 10(2): 125134. ［20］ Mullighan CG, Miller CB, Radtke I, et al. BCRABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros［J］. Nature, 2008, 453(7191): 110114. ［21］ Medeiros BC. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia［J］. N Engl J Med, 2009, 360(17): 470480. ［22］ Krentz S, Hof J, Mendioroz A, et al. Prognostic value of genetic alterations in children with first bone marrow relapse of childhood Bcell precursor acute lymphoblastic leukemia［J］. Leukemia, 2013, 27(2): 295304. ［23］ van der Veer A, Zaliova M, Mottadelli F, et al. IKZF1 status as a prognostic feature in BCRABL1positive childhood ALL［J］. Blood, 2014, 123(11): 16911698.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266.
[4]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[5]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei.Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction[J]. Journal of International Oncology, 2024, 51(4): 193-197.
[6]	Wan Fang, Yang Gang, Li Rui, Wan Qijing.Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer[J]. Journal of International Oncology, 2024, 51(4): 204-209.
[7]	Yao Yixin, Shen Yulin.Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE[J]. Journal of International Oncology, 2024, 51(4): 217-222.
[8]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao.Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes[J]. Journal of International Oncology, 2024, 51(3): 143-150.
[9]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180.
[10]	Peng Qin, Cai Yuting, Wang Wei.Advances on KPNA2 in liver cancer[J]. Journal of International Oncology, 2024, 51(3): 181-185.
[11]	Teng Yuan, Li Lijuan, Zhang Liansheng.Progress of MCL-1 and its inhibitors in hematologic malignancies[J]. Journal of International Oncology, 2024, 51(2): 119-122.
[12]	Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82.
[13]	Jin Xudong, Chen Zhongjian, Mao Weimin.Research progress on the role of MTAP in malignant mesothelioma[J]. Journal of International Oncology, 2024, 51(2): 99-104.
[14]	Huang Zhen, Chen Yongshun.Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma[J]. Journal of International Oncology, 2024, 51(1): 59-64.
[15]	Wang Xiao, Li Ying, Luo Yujie, Jin Shu.Study on the prognostic value of serological indicators for nasopharyngeal carcinoma based on nomogram model[J]. Journal of International Oncology, 2023, 50(8): 463-469.

Ikaros and childhood acute lymphoblastic leukemia

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments